12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Truvada emtricitabine/tenofovir regulatory update

FDA's Antiviral Drugs Advisory Committee concluded the benefit-risk profile for Truvada emtricitabine/tenofovir supports the drug's use as pre-exposure prophylaxis (PrEP) to reduce risk of HIV-1 infection in uninfected adults. The panel voted 19-3 in favor of recommending approval of...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >